Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Titel:
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Auteur:
Garcia-Sanz, R. Sureda, A. de la Cruz, F. Canales, M. Gonzalez, A.P. Pinana, J.L. Rodriguez, A. Gutierrez, A. Domingo-Domenech, E. Sanchez-Gonzalez, B. Rodriguez, G. Lopez, J. Moreno, M. Rodriguez-Salazar, M.J. Jimenez-Cabrera, S. Caballero, M.D. Martinez, C.